Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study

barbara.lempert

Top 2 and Late-Breaker Presentation at ICAAC

  —  Encouraging results from the first proof-of-concept study for adenovirus
      infection support continued clinical development of CMX001 as a
      first-in-class broad-spectrum antiviral for prevention of
      double-stranded DNA viral infections

  —  Data accepted for oral late-breaker presentation at the ICAAC Annual
      Meeting on September 10th

DURHAM, N.C., Aug. 14, 2013 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced top line data from the exploratory Phase 2 study of CMX001 as preemptive therapy for adenovirus (AdV) infection, the first interventional trial in AdV infection. In this trial in allogeneic hematopoietic cell transplant (HCT) recipients, the 100 mg dose given twice weekly (BIW) demonstrated decreased levels of AdV viremia and showed a potential benefit in reducing both progression to AdV disease and all-cause mortality, compared to subjects who received placebo or CMX001 given once weekly (QW). Planned intent-to-treat analyses as well as exploratory analyses in specific patient groups were consistent in trends favoring the CMX001 BIW regimen over placebo, although statistical significance was not established in this exploratory study.

Chimerix also announced the acceptance of the proof-of-concept data as an oral late-breaker presentation at the upcoming 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) meeting being held in Denver, CO on September 10-13, 2013.

“These proof of concept data will provide critical information regarding the factors that predict an increased risk of AdV infection and the natural history of AdV infection that too often leads to devastating morbidity and mortality in…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS